All In Biotech

Drug Trial Radar · NCT01367665

STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)

Last checked: Nov 20, 2026Latest source record: Jun 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,232

Actual

Start

Jul 1, 2011

Primary completion

Jun 14, 2017

Study completion Jun 14, 2017

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 7, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This single-arm, open-label, multi-center study will evaluate the safety and efficacy of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma. Patients will receive oral doses of vismodegib 150 mg once daily until disease progression or unacceptable toxicity.

Conditions

  • Basal Cell Carcinoma

Interventions

  • vismodegibDrug

    150 mg once daily until disease progression or unacceptable toxicity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs)Time frame: Baseline to the data cut-off of 14 June 2017 (up to 6 years)
  2. Percentage of Participants Who Died Due to Adverse Events, Disease Progression or Other ReasonsTime frame: Baseline to the data cut-off of 14 June 2017 (up to 6 years)
  3. Percentage of Participants Who Report a Shift in NCI CTCAE Grades to 3/4 in Hematology and Biochemistry Laboratory ParametersTime frame: Baseline to the data cut-off of 14 June 2017 (up to 6 years)
  4. Exposure to Study Treatment: Duration on TreatmentTime frame: Baseline to the data cut-off of 14 June 2017 (up to 6 years)
  5. Exposure to Study Treatment - Dose IntensityTime frame: Baseline to the data cut-off of 14 June 2017 (up to 6 years)

Locations

181 sites in 37 countries. Site status is shown where the registry gives one.

  • Inst. de Oncologia Angel H. Roffo ; Servicio de Oncologia

    Buenos Aires, Argentina

  • Premier Specialists

    Kogarah, New South Wales, Australia

  • Skin and Cancer Foundation Australia

    Westmead, New South Wales, Australia

  • CMAX A division of IDT Australia Limited

    Adelaide, South Australia, Australia

  • Skin & Cancer Foundation

    Carlton, Victoria, Australia

  • LKH Graz; Abteilung für allgemeine Dermatologie

    Graz, Austria

  • LKH Salzburg; Universitätsklinik für Dermatologie

    Salzburg, Austria

  • Landesklinikum St. Pölten

    Sankt Pölten, Austria

  • Medizinische Universität Wien; Univ.Klinik für Dermatologie

    Vienna, Austria

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • University Clinical Center of the Republic of Srpska

    Banja Luka, Bosnia and Herzegovina

  • Clinic of Oncology, University Clinical Center Sarajevo

    Sarajevo, Bosnia and Herzegovina

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Cancer de Barretos

    Barretos, São Paulo, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, Brazil

  • District Oncology Dispensary; Department for Oncology and Dermatology

    Plovdiv, Bulgaria

  • National Specialized Hospital for Active Oncology Treatment; Dermatology Clinic

    Sofia, Bulgaria

  • Centre de Recherche Dermatologique du Quebec Metropolitain (CRDQ)

    Québec, Canada

  • Western Canada Dermatology Institute

    Edmonton, Alberta, Canada

  • Cancer Care Manitoba

    Winnipeg, Manitoba, Canada

  • London Regional Cancer Centre

    London, Ontario, Canada

  • Dr. Nowell Solish Cosmetic Dermatology

    Toronto, Ontario, Canada

  • Victoria Park MediSpa

    Montreal, Quebec, Canada

  • Inst. Nacional de Cancerologia; Clinica de Seno

    Bogotá, Colombia

  • Riesgo De Fractura; Rheumatology

    Bogotá, Colombia

  • Hemato Oncologos S.A.

    Cali, Colombia

  • Reumalab Sas; Rheumatology

    Medellín, Colombia

  • Hospital Pablo Tobon Uribe

    Medellin-Antioquia, Colombia

  • Clinical Hospital Sisters of Mercy

    Zagreb, Croatia

  • Nemocnice Ceske Budejovice

    České Budějovice, Czechia

  • Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology

    Hradec Králové, Czechia

  • Fakultní nemocnice Ostrava; Kožní oddělení

    Ostrava, Czechia

  • Fakultni nemocnice Kralovske Vinohrady

    Prague, Czechia

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia

  • Fakultni Thomayerova Nemocnice; Onkologicke Oddeleni

    Prague, Czechia

  • Fakultni nemocnice v Motole

    Prague, Czechia

  • Herlev Hospital; Onkologisk afdeling

    Herlev, Denmark

  • Helsinki University Central Hospital; Skin & Allergy Hospital

    Helsinki, Finland

  • Kuopion yliopistollinen sairaala

    Kuopio, Finland

  • Hopital Saint Andre CHU De Bordeaux; Dermatologie

    Bordeaux, France

Showing 40 of 181 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.